A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study.
Fenske TS, Shah NM, Kim KM, Saha S, Zhang C, Baim AE, Farnen JP, Onitilo AA, Blank JH, Ahuja H, Wassenaar T, Qamar R, Mansky P, Traynor AM, Mattison RJ, Kahl BS.
Fenske TS, et al. Among authors: kahl bs.
Cancer. 2015 Oct 1;121(19):3465-71. doi: 10.1002/cncr.29502. Epub 2015 Jun 16.
Cancer. 2015.
PMID: 26079295
Free article.
Clinical Trial.